A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies
Prelude Therapeutics
Prelude Therapeutics
Dana-Farber Cancer Institute
Kahr Medical
Eli Lilly and Company
OHSU Knight Cancer Institute
Prelude Therapeutics